China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
Board of Directors 2025 Annual Work Report
Dear Shareholders:
China Resources Sanjiu adheres to the guidance of Xi Jinping's Thought on Socialism with Chinese Characteristics for a New Era, upholding the principle of "two unifications," and fully implementing the important instructions and decisions of the Party Central Committee and the State Council, continuously enhancing the company's core competitiveness.
In 2025, China Resources Sanjiu successfully concluded the "14th Five-Year Plan." The Board of Directors fully exercised its responsibilities in "defining strategy, making decisions, and preventing risks," focusing on the main line of high-quality development, continuously strengthening the construction of the Board, and promoting the implementation of strategic development requirements. All directors diligently performed their duties, adhered to scientific and prudent decision-making, earnestly implemented the resolutions passed by the shareholders' meeting, actively fulfilled the responsibilities entrusted by the company and shareholders, and effectively safeguarded the interests of the company and the legitimate rights and interests of all shareholders. At the same time, we closely monitored regulatory dynamics and capital market trends, continuously building a solid risk compliance defense line, laying a solid foundation for the company to smoothly enter the new stage of development in the "15th Five-Year Plan."
The following is the annual work report of the Board of Directors:
Part One: 2025 Annual Work Report
I. Play the Core Role of the Board of Directors and Continuously Enhance Governance Level
(1) Promote Strategic Development and Play the Board's Role in "Defining Strategy"
-
Grasp Strategic Direction and Build Consensus on Development
In 2025, facing a complex and changing economic and market environment, the pharmaceutical industry persevered. In response to profound changes in the internal and external environment, China Resources Sanjiu anchored its corporate mission of "Caring for Public Health and Creating a Better Life." Under the leadership of the Board of Directors, the company adhered to the dual drive of "Innovation + Brand," steadily advancing in a complex market environment. -
Emphasize Strategic Planning Discussions and Promote a Smooth Start to the "15th Five-Year Plan"
To solidly advance the implementation and connection of strategies, the company conducted a summary of the "14th Five-Year Plan" strategy and discussions on the "15th Five-Year Plan" strategy, systematically reviewing the execution effectiveness and practical experience during the "14th Five-Year Plan" period, exploring the development space and transformation challenges of the pharmaceutical industry under the new situation, further building consensus on development, and promoting a smooth transition and strategic upgrade from the "14th Five-Year Plan" to the "15th Five-Year Plan." The goal of doubling revenue during the "14th Five-Year Plan" has been successfully achieved, laying a solid foundation for the next stage of high-quality development.
(2) Make Scientific and Rational Decisions, Play the Board's Role in "Making Decisions"
- Conduct Major Decisions in a Scientific, Standardized, and Prudent Manner
The Board of Directors has always adhered to standardized operations and scientific decision-making. In 2025, the Board held 15 meetings and reviewed 94 proposals. The regulations, economic contracts, and important decisions reviewed by the Board were all legally vetted in advance. The convening and voting procedures of each meeting complied with the Company Law and other relevant laws and regulations, as well as the Articles of Association and the Rules of Procedure for Board Meetings, with strict adherence to the voting system, ensuring that the voting results were legal and valid.